A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies
Authors:
- Philippe De La RocherePRPhilippe De La Rochere
- Laure LoumagneLLLaure Loumagne
- Melanie RathauxMRMelanie Rathaux
- Marine DuboisMDMarine Dubois
- Fariba NematiFNFariba Nemati
- Sophie VielSVSophie Viel
- Tamara SlavnicTSTamara Slavnic
- Jayant ThatteJTJayant Thatte
- Qixiang Li HenryQHQixiang Li Henry
- Xuesong OuyangXOXuesong Ouyang
- Christine SedlikCSChristine Sedlik
- Didier DecaudinDDDidier Decaudin
Preprint
Abstract
Humanized immune system (HIS) mouse models, generated by engrafting tumors and hematopoietic cells of human (Hu) origin into immunodeficient host mice, effectively recapitulate key aspects of the crosstalk between human immune cells and tumors. These models represent a valuable tool for the preclinical evaluation of immunotherapies. In this study, we provide a comprehensive comparison of two widely used HIS models: the Hu-CD34+ model, which engrafts Hu-hematopoietic cells derived from Hu-CD34+ hematopoietic stem cells (HSCs), and the Hu-PBMC model, which utilizes Hu-peripheral blood mononuclear cells (PBMCs). We assess the kinetics, quality and extent of immune cell engraftment, as well as the development of graft-versus-host disease (GVHD). Additionally, we investigate the impact of different immunodeficient host mouse strains on immune cell reconstitution in the Hu-CD34+ model. Both HIS models were engrafted with human tumors derived from either cell lines or patient-derived xenografts (PDX), revealing distinct immune-tumor interactions that influenced antitumor responses. Notably, tumor responses to T-cell-directed therapies, including anti-PD1 antibodies, IL-2-anti-IL-2 antibody complexes, and T-cell engagers, varied across these models. Our findings provide novel insights into the properties and limitations of HIS models, offering a critical resource for optimizing next-generation immuno-oncology strategies and guiding the design of future therapeutic interventions.Keywords
All Related Versions
- Published version: Frontiers in Immunology, 17, 1730378.
Funding Information
- Institut Curie (PIC3i-2015)
- Agence Nationale de la Recherche, LabEx DCBIOL (ANR-10-IDEX-0001-02 PSL and ANR-11-LABX0043)
- Center of Clinical Investigation (CIC IGR-Curie 1428)
- Agence Nationale de la Recherche (ANR-15-CHIND-0002)
This publication has 24 references indexed in Scilit:
- Progress, implications, and challenges in using humanized immune system mice in CAR‐T therapy—Application evaluation and improvementAnimal Models and Experimental Medicine, 2023
- Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapyCancer Cell, 2023
- First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialJournal of Thoracic Oncology, 2022
- An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancerGynecologic Oncology, 2020
- Humanized Mice for the Study of Immuno-OncologyTrends in Immunology, 2018
- Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse modelNature Communications, 2017
- Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host diseaseImmunology Letters, 2014
- Functional CD47/signal regulatory protein alpha (SIRPα) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivoProceedings of the National Academy of Sciences, 2011
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsProceedings of the National Academy of Sciences, 2010
- PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2European Journal of Immunology, 2002